CRISPR/Cas9 technology in the modeling of and evaluation of possible treatments for Niemann-Pick C.

Autor: Reyhani-Ardabili M; Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Fathi M; Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Ghafouri-Fard S; Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran. s.ghafourifard@sbmu.ac.ir.
Jazyk: angličtina
Zdroj: Molecular biology reports [Mol Biol Rep] 2024 Jul 20; Vol. 51 (1), pp. 828. Date of Electronic Publication: 2024 Jul 20.
DOI: 10.1007/s11033-024-09801-1
Abstrakt: Niemann-Pick disease type C (NPC) is a rare neurodegenerative condition resulted from mutations in NPC1 and NPC2 genes. This cellular lipid transferring disorder mainly involves endocytosed cholesterol trafficking. The accumulation of cholesterol and glycolipids in late endosomes and lysosomes results in progressive neurodegeneration and death. Recently, genome editing technologies, particularly CRISPR/Cas9 have offered the opportunity to create disease models to screen novel therapeutic options for this disorder. Moreover, these methods have been used for the purpose of gene therapy. This review summarizes the studies that focused on the application of CRISPR/Cas9 technology for exploring the mechanism of intracellular cholesterol transferring, and screening of novel agents for treatment of NPC.
(© 2024. The Author(s), under exclusive licence to Springer Nature B.V.)
Databáze: MEDLINE
Externí odkaz: